内美通治疗子宫内膜异位症的临床研究
子宫内膜异位症,内美通,子宫内膜异位症,治疗,1资料和方法,1.2方法,2结果,3讨论,参考文献
【摘要】 目的 评价内美通治疗子宫内膜异位症的临床效果及副反应。方法 子宫内膜异位症患者40例,给予内美通口服,每周2次,用药1年。观察症状、子宫及异位囊肿体积改变;血清E 2 、CA 125 变化;副反应发生情况。结果 治疗前26例有不同程度痛经,治疗3月后,20例诉痛经明显减轻或无痛经,治疗1年后均无痛经表现。治疗前子宫体积672.58±409.39cm 3 ,治疗后528.32±357.66cm 3 ,较治疗前缩小,差异有显著性(P<0.05)。治疗前血清E 2 为257.47±187.62pmol/L,治疗后血清E 2 较治疗前略有降低,为223.49±135.69pmol/L,但差异无显著性。除月经少许改变外,未见严重副反应。结论 内美通治疗子宫内膜异位症安全有效,有价格低、给药方便等特点,适合于成年妇女子宫内膜异位症的保守治疗。关键词 内美通 子宫内膜异位症 治疗
The clinical applicd research about gestrinone treating endometriosis
FanQin,Bai Hongzhen,Zhou Zhijie
Department of Obstetrics and Gynecology,
Baogang Hospital,Medical University Second Shanghai,201900.
【Abstract】 Objective To study the response of endometriosis to treatmentof Gestrinone acetate.Methods 40patients with endometriosis were by Gestrinone two times per every weak for1year.Volume of uterus and enˉdometriosis were measured by ultrasonography before and after therapy:E 2 concentration in the serum were detected at the same time.Results Symptoms Of dysmenorrhea were improved greatly.Volume of uterus was decreased(P<0.05) ......
您现在查看是摘要页,全文长 7071 字符。